Pulmonary Fibrosis
📧 Sign up to get email alerts when something new happens for Pulmonary Fibrosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-25EMA Authorised: Nintedanib Accord (nintedanib) — Accord Healthcare S.L.U.
EU authorization of Nintedanib Accord for idiopathic pulmonary fibrosis and related interstitial lung diseases, expanding treatment options …
-
EMA approval · 2026-01-06EMA Authorised: Ofev (nintedanib) — Boehringer Ingelheim International GmbH
The European Medicines Agency authorised a label expansion for Ofev (nintedanib) to cover additional interstitial lung diseases, including s…
-
EMA approval · 2025-09-05EMA Authorised: Nintedanib Viatris (nintedanib) — Viatris Limited
The European Medicines Agency authorised a generic version of nintedanib (Nintedanib Viatris) for idiopathic pulmonary fibrosis and related …
-
EMA approval · 2025-08-29EMA Authorised: Nintedanib Accord (nintedanib) — Accord Healthcare S.L.U.
The EMA authorised Nintedanib Accord for indications including Idiopathic Pulmonary Fibrosis, interstitial lung diseases, systemic sclerosis…